Ascendis Pharma A/S
ASND
Pozycja w akcjach
#1550
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Cena akcji
$224.87
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$14.03B
Zmiana (1 dzień)
-0.77%
Zmiana (1 rok)
6.83%
Kraj
DK
Handel Ascendis Pharma A/S (ASND)
Kategoria
Healthcare
EPS dla Ascendis Pharma A/S (ASND)
EPS na dzień June 2026 TTM: $14.35
Według najnowszych raportów finansowych i ceny akcji firmy Ascendis Pharma A/S, obecny EPS (TTM) wynosi $14.35. Na koniec roku 2024 firma miała EPS w wysokości $-6.79, spadek w porównaniu do do EPS z roku 2023, który wynosił $-9.45.
Historia EPS dla Ascendis Pharma A/S od 2012 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $14.35 | -437.71% |
| 2025 | $-4.25 | -37.49% |
| 2024 | $-6.79 | -28.11% |
| 2023 | $-9.45 | -15.28% |
| 2022 | $-11.16 | 40.15% |
| 2021 | $-7.96 | -21.06% |
| 2020 | $-10.08 | 91.63% |
| 2019 | $-5.26 | 44.45% |
| 2018 | $-3.64 | -17.50% |
| 2017 | $-4.42 | 62.66% |
| 2016 | $-2.71 | 79.86% |
| 2015 | $-1.51 | 118.83% |
| 2014 | $-0.69 | -231.97% |
| 2013 | $0.52 | 230.13% |
| 2012 | $0.16 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | 20.68% |
US
|
|
| $-7.98 | -155.60% |
US
|
|
| $-5.29 | -136.86% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 93.28% |
NL
|
